Clinical Trials Logo

Retinitis Pigmentosa clinical trials

View clinical trials related to Retinitis Pigmentosa.

Filter by:

NCT ID: NCT05355415 Recruiting - Clinical trials for Age-Related Macular Degeneration

Adaptive Optics Imaging of Outer Retinal Diseases

Start date: August 27, 2021
Phase:
Study type: Observational

The objective of the study is to collect adaptive optics (AO) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor, retinal pigment epithelium (RPE), basement membrane or choroidal pathologies) to develop new diagnostic methods, biomarkers, and clinical endpoints.

NCT ID: NCT05285618 Completed - Clinical trials for Retinitis Pigmentosa

The Perceptual Experience of Argus II Users

Start date: January 11, 2022
Phase: N/A
Study type: Interventional

The goal of this project is to quantify and computationally model the perceptual experiences of Argus II retinal prosthesis patients. The investigators will produce visual percepts in patients either by directly stimulating electrodes or by asking them to view a computer or projector screen and using standard FDA-approved stimulation protocols (as is standardly used for their devices) to convert the computer or projector screen image into pulse trains on their electrodes. Performance of patients will be compared to that of sighted control subjects viewing a simulation of the vision generated by Argus II in virtual reality.

NCT ID: NCT05282953 Recruiting - Clinical trials for Retinitis Pigmentosa

A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)

Start date: November 10, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A phase I/II dose-escalating study of the safety, tolerability and efficacy of KIO-301 administered intravitreally to patients with retinitis pigmentosa and choroideremia (ABACUS). Open label.

NCT ID: NCT05258032 Recruiting - Clinical trials for Retinitis Pigmentosa

Structural and Functional Characterization of Rare Ocular Diseases

RADIS
Start date: November 24, 2021
Phase:
Study type: Observational

Rare ocular diseases (ROD) are a heterogeneous group of ocular diseases that affect very few people and, generally, for which no tretament is available. An important subgroup of these diseases are inherited retinal degenerations. In this study we focus on understanding the natural history of different ROD that affect the posterior segment.

NCT ID: NCT05203939 Recruiting - Clinical trials for Retinitis Pigmentosa

Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis

Start date: January 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 in patients with retinitis pigmentosa associated with NR2E3 and RHO mutations and in patients with LCA due to mutation(s) in CEP290 gene (OCU400-101). To document prospective eye pathology in the above subjects Investigators will also conduct a Natural History Study (OCU400-104)i This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 24 subjects in the OCU400-101 and 100 subjects in the OCU400-104 study.

NCT ID: NCT05179460 Completed - Clinical trials for Interstitial Cystitis

A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy

Start date: October 26, 2021
Phase:
Study type: Observational

The purpose of this study is to evaluate incidence and prevalence rates of the study endpoints (pigmentary maculopathy [PM]/ pigmentary retinopathy [PR]/Any, PM/PR/ pentosan polysulfate sodium [PPS], and PM/PR/Non-PPS) in relation to PPS exposure, and in participants with interstitial cystitis (IC) but not exposed to PPS; changes in visual acuity (VA) over time; participant treatment journey leading to PPS treatment, and potential risk factors associated with the occurrence of PM/PR/PPS.

NCT ID: NCT05176717 Terminated - Clinical trials for Retinitis Pigmentosa

Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)

Start date: December 15, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy safety and tolerability of QR-421a administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene with early to moderate vision loss.

NCT ID: NCT05158296 Active, not recruiting - Clinical trials for Retinitis Pigmentosa

Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

Start date: December 8, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.

NCT ID: NCT05158049 Enrolling by invitation - Clinical trials for Retinitis Pigmentosa

Longitudinal Study of a Bionic Eye

Start date: December 9, 2021
Phase:
Study type: Observational

This is a longitudinal observational study with participants who have been implanted with the suprachoroidal retinal prosthesis.

NCT ID: NCT05147701 Recruiting - Glaucoma Clinical Trials

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Eye Diseases

Start date: February 1, 2022
Phase: Phase 1
Study type: Interventional

This trial will study the safety and efficacy of intravenous and sub-tenon delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Eye diseases